Migraine, unspecified, not intractable, without status migrainosus
ICD-10 Code: G43.909 · Body Part: Head/Brain (TBI)
QME Evaluation Process
Headache history, frequency and severity assessment, imaging to rule out structural cause. May be secondary to TBI. Brain impairment per Chapter 13.
Typical Impairment Rating
0-14% WPI based on frequency and medication responsiveness
AMA Guides Edition
5th Edition
Common Treatments
Related Conditions
Body Part Guide
Head/Brain (TBI) Evaluation Guide
Impairment rating methods, common conditions, and QME evaluation protocols
QME Specialties for Migraine, unspecified, not intractable, without status migrainosus
Find a QME Specialist
Browse QME-certified physicians who evaluate migraine, unspecified, not intractable, without status migrainosus and related head/brain (tbi) conditions in California.
Browse Neurology Physicians →Frequently Asked Questions
What is Migraine, unspecified, not intractable, without status migrainosus (G43.909)?
Migraine, unspecified, not intractable, without status migrainosus is an ICD-10 diagnosis code (G43.909) classified under Neurological conditions. It affects the Head/Brain (TBI) and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.
How is G43.909 rated for impairment?
The typical whole person impairment (WPI) range for Migraine, unspecified, not intractable, without status migrainosus is 0-14% WPI based on frequency and medication responsiveness. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.
What is the QME evaluation process for G43.909?
Headache history, frequency and severity assessment, imaging to rule out structural cause. May be secondary to TBI. Brain impairment per Chapter 13.
What treatments are common for Migraine, unspecified, not intractable, without status migrainosus?
Common treatments for Migraine, unspecified, not intractable, without status migrainosus include Prophylactic medication, Triptans for acute episodes, Botox injections, Biofeedback. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.